KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biolife Solutions (BLFS) EBT Margin (2016 - 2025)

Biolife Solutions (BLFS) has disclosed EBT Margin for 16 consecutive years, with 17.9% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 1479.0% to 17.9% in Q4 2025 year-over-year; TTM through Dec 2025 was 12.56%, a 74.0% decrease, with the full-year FY2025 number at 12.56%, down 74.0% from a year prior.
  • EBT Margin was 17.9% for Q4 2025 at Biolife Solutions, up from 2.5% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 17.9% in Q4 2025 to a low of 290.58% in Q4 2023.
  • A 5-year average of 52.43% and a median of 24.38% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: plummeted -19006bps in 2021, then skyrocketed 29369bps in 2024.
  • Biolife Solutions' EBT Margin stood at 49.12% in 2021, then tumbled by -342bps to 217.31% in 2022, then tumbled by -34bps to 290.58% in 2023, then soared by 101bps to 3.1% in 2024, then skyrocketed by 477bps to 17.9% in 2025.
  • Per Business Quant, the three most recent readings for BLFS's EBT Margin are 17.9% (Q4 2025), 2.5% (Q3 2025), and 61.81% (Q2 2025).